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Background
The current GENCODE gene count of ~ 30,000, includ-
ing 21,727 protein-coding and 8,483 RNA genes, is sig-
nificantly lower than the 100,000 genes anticipated by
early estimates. Accurate annotation of protein-coding
and non-coding genes and pseudogenes is essential in
calculating the true gene count and gaining insight into
human evolution.
As part of the GENCODE Consortium, the HAVANA
team produces high quality manual gene annotation,
which forms the basis for the reference gene set being
used by the ENCODE project and provides a rich anno-
tation of alternative splice variants and assignment of
functional potential. However, the protein-coding poten-
tial of some splice variants is uncertain and valid splice
variants can remain unannotated if they are absent from
current cDNA libraries. Recent technological develop-
ments in sequencing and mass spectrometry have cre-
ated a vast amount of new transcript and protein data
that facilitate the identification and validation of new
and existing transcripts, while harboring their own lim-
itations and problems.
Results
Historically, all gene models have been built based on
support from mRNA, EST and protein evidence. The
recent integration of RNA-seq data into our annotation
pipeline has allowed us to identify new splice variants
that were previously either unannotated or supported
only by non-human transcript evidence. Owing to their
short read length, however, mapping them to the gen-
ome is problematic as is their use in recapitulating full-
length transcript models. In order to assess different
computational methods to map, assemble and quantify
human RNA-seq data and improve this pipeline, we
have been involved in the RNA-seq Genome Annotation
Assessment project (RGASP), which seeks to address
these questions.
We will also present the use of CAGE and ditag data
produced by the ENCODE transcriptome group to iden-
tify and verify the use of alternative transcription start
and termination sites and describe their impact on the
interpretation of coding potential. Finally, we will show
how mass spectrometry data can validate annotated
gene models, identify novel splice variants and lead us
to change our interpretation of the functional potential
of a locus or variant.
Conclusions
We believe that an understanding of complete gene sets
(i.e. the total gene number and the number of alterna-
tive splice variants allied to accurate functional interpre-
tation) is crucial for understanding the genome. We
demonstrate the value of the integration of new data
types into our annotation pipeline in helping to identify
and validate loci and variants to reach this aim.
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